

18:30 **Cocktail Reception**

19:00 **Dinner**

19:30 **Greetings**

- **Prof. Adir Yochai**, MD. Chairman of the Israeli Society of the Pulmonology medicine, Director of pulmonary division Carmel Medical center.
- **Prof. Ahron Kesel**, MD. Chairman of the Israeli Society of Allergy and Clinical immunology, Director Allergy division Bney Zion Medical center.

19:45 **Interactive cases presentations**

- **Prof. Mordechai R. Kramer**, MD. Director of the Institute of Pulmonary and Allergy Medicine – Beilinson Medical Center.
- **Prof. Nancy Agmon- Levin**, Head of the Clinical Immunology, Angioedema and Allergy Unit Sheba Medical center.

20:05 **Monoclonal Antibody Therapy for the Management of Asthma: Eosinophils and Beyond**

Roland Kolbeck, Ph.D VP, R&D Respiratory, Inflammation and Autoimmunity (RIA)- Medimmune.

20:45 **Anti IL-5: what can we learn from published data and clinical experience**

Bradley E. Chipps, MD-FAAP, FAAAAI, FCCP, President, President of the American College of Allergy, Asthma & Immunology.

21:25 **Discussion**

אישורי הגעה:

איריס טרגנו 053-9235507, מיה לוי 052-7206044


Fasenra[®]
(benralizumab) Subcutaneous
injection 30 mg


45240 פרשת ה'תש"פ, ת"ת 6 ש"ת, 1455, ת"ת ה'תש"פ, AstraZeneca

Dr. Kolbeck is an accomplished investigator and science leader in the field of immunology and inflammation. During his tenure, Dr. Kolbeck has provided scientific oversight and leadership for the advancement of over 30 drug discovery programmes — from target discovery through early stages of clinical development.



Roland Kolbeck, Ph.D VP, R&D Respiratory, Inflammation and Autoimmunity (RIA) - Medimmune


Dr. Chipps took part in Benralizumab's studies, CALIMA pivotal study and BORA extension study. He published a unique data of Benralizumab efficacy by atopy status and serum immunoglobulin E. On this evening he will share his long standing experience with biologic drugs for severe asthmatic patients.



Bradley E. Chipps, MD-FAAP, FACAAI, FAAAAI, FCCP, President of the American College of Allergy Asthma & Immunology

Fasenra[®]
(benralizumab) Subcutaneous Injection 30 mg

POWER TO INSPIRE Fasenra's launch Israel



Monday December 3rd - 18:30 Crown Plaza Azrieli,
Menachem Begin 132, Tel Aviv

AstraZeneca 